Over the past decades, ManRos Therapeutics' collaborators have extensively described several families of kinases, and characterized several inhibitors.
Below is a selection of related scientific publications:
CDK inhibitors
Knockaert, M., Greengard, P. and Meijer, L., 2002. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 23, 417-425.
Download this publication.
R-roscovitine and analogues
Meijer, L., Bettayeb, K. and Galons, H., 2006. R-roscovitine (CYC202, Seliciclib). In “Monographs on enzyme inhibitors”, Volume 2. CDK inhibitors and their potential as anti-tumor agents » (E. Yue and P.J. Smith, editors). CRC Press, Taylor & Francis, chapter 9, 187-226.
Download this publication.
Meijer, L. and Raymond, E., 2003. R-roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Accounts Chem. Res. 36, 417-425.
Download this publication.
Bach, S., Knockaert, M., Lozach, O., Reinhardt, J., Baratte, B., Schmitt, S., Coburn, S.P., Tang, L., Jiang. T., Liang, D.C., Galons, H., Dierick, J.F., Totzke, F., Schächtele, C., Lerman, A.S., Carnero, A., Wan, Y., Gray, N. and Meijer, L., 2005. R-roscovitine targets: protein kinases and pyridoxal kinase. J. Biol. Chem. 280, 31208-31219.
Download this publication.
Gray, N., Wodicka, L., Thunnissen, A. M., Norman, T., Kwon, S., Espinoza, F.H., Morgan, D.O., Barnes, G., Leclerc, S., Meijer, L., Kim, S.H., Lockhart, D.J. and Schultz, P.G., 1998. Exploiting chemical libraries, structure, and genomics in the search for new kinase inhibitors. Science 281, 533-538.
Download this publication.
Azevedo, W.F., Leclerc, S., Meijer, L., Havlicek, L., Strnad, M. and Kim, S.H., 1997. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with R-roscovitine. Eur. J. Biochem. 243, 518-526.
Download this publication.
Meijer, L., Borgne, A., Mulner, O., Chong, J.P.J., Blow, J.J., Inagaki, N., Inagaki, M., Delcros, J.G. and Moulinoux, J.P., 1997. Biochemical and cellular effects of R-roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243, 527-536.
Download this publication.
Vesely, J., Havlicek, L., Strnad, M., Blow, J. J., Donella-Deana, A., Pinna, L., Letham, D.S., Kato, J.Y., Détivaud, L., Leclerc, S. and Meijer, L., 1994. Inhibition of cyclin-dependent kinases by purine derivatives. Eur. J. Biochem. 224, 771-786.
Download this publication.
GSK-3 inhibitors
Meijer, L., Flajolet, M. and Greengard, P., 2004. Pharmacological inhibitors of glycogen synthase kinase-3. Trends Pharmacol. Sci. 25, 471-480.
Download this publication.